You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

carfilzomib

Showing 26 - 50 of 159
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Carfilzomib
  • +2 more
  • (no location specified)
Aug 8, 2022

Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Sep 20, 2023

Multiple Myeloma Trial in United States (Carfilzomib, Pomalidomide, Dexamethasone)

Terminated
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Atlanta, Georgia
  • +8 more
Jul 28, 2022

Hematologic Malignancies, Relapse, GVHD Trial in Ann Arbor (Carfilzomib, Tacrolimus)

Completed
Has Results
  • Hematologic Malignancies
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Hospital
Dec 3, 2021

Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)

Recruiting
  • Multiple Myeloma in Relapse
  • Aurora, Colorado
    University of Colorado Hospital
Jan 31, 2023

Refractory Multiple Myeloma Trial in United States (selinexor, carfilzomib, dexamethasone)

Recruiting
  • Refractory Multiple Myeloma
  • Scottsdale, Arizona
  • +4 more
Apr 1, 2022

Relapsed Solid Tumors, Refractory Solid Tumors, Relapsed Leukemia Trial in Canada, United States (Carfilzomib, Cyclophosphamide,

Recruiting
  • Relapsed Solid Tumors
  • +3 more
  • Carfilzomib
  • +2 more
  • Phoenix, Arizona
  • +7 more
Apr 12, 2022

Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)

Recruiting
  • Multiple Myeloma
  • Selinexor 60 MG
  • +6 more
  • Washington, District of Columbia
  • +1 more
Feb 3, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Chemosensitivity Assay,

Terminated
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 6, 2022

Smouldering Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Lenalidomide)

Recruiting
  • Smouldering Myeloma
  • Carfilzomib
  • +2 more
  • Brno, Czechia
  • +15 more
Mar 22, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +4 more
  • Des Moines, Iowa
  • +8 more
Jan 12, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 3, 2022

Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 5, 2021

Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +3 more
  • Boston, Massachusetts
  • +2 more
Oct 28, 2021

Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
Nov 18, 2021

Multiple Myeloma Trial in Canada, United States (Pomalidomide, Carfilzomib, dexamethasone)

Recruiting
  • Multiple Myeloma
  • Chicago, Illinois
  • +4 more
Jan 7, 2022

Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult

Completed
  • Contiguous Stage II Adult Lymphoblastic Lymphoma
  • +5 more
  • carfilzomib
  • +10 more
  • Sacramento, California
    University of California Davis
Mar 8, 2022

Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +4 more
  • Birmingham, Alabama
  • +11 more
Aug 11, 2022

Multiple Myeloma Trial in Sweden, United States (Bortezomib, Dexamethasone, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Miami, Florida
  • +8 more
Nov 23, 2021

Myeloma, Multiple Myeloma Trial in Chicago (Daratumumab, Carfilzomib, Lenalidomide)

Recruiting
  • Myeloma
  • Multiple Myeloma
  • Chicago, Illinois
    The University of Chicago
Sep 15, 2021

Multiple Myeloma Trial in Chicago, Evanston, Ann Arbor (Elotuzumab, Carfilzomib, Lenalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Chicago, Illinois
  • +2 more
Nov 12, 2021

Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple Trial in Israel (Carfilzomib, Daratumumab, Lenalidomide)

Completed
  • Myeloma Multiple
  • +3 more
  • Carfilzomib
  • +3 more
  • Afula, Israel
  • +13 more
Jan 26, 2022

Multiple Myeloma Trial in United States (panobinostat, carfilzomib)

Completed
Has Results
  • Multiple Myeloma
  • Denver, Colorado
  • +12 more
Jan 4, 2022

Multiple Myeloma Trial in Canada (Carfilzomib, Cyclophosphamide, Dexamethasone)

Completed
Has Results
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Edmonton, Alberta, Canada
  • +8 more
Feb 1, 2022

Relapsed/Refractory Multiple Myeloma Trial in Worldwide (BGB-11417, Dexamethasone, Carfilzomib)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Birmingham, Alabama
  • +21 more
Aug 8, 2022